Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Operating Leases (2019 - 2025)

Utah Medical Products has reported Operating Leases over the past 7 years, most recently at $256000.0 for Q2 2025.

  • Quarterly results put Operating Leases at $256000.0 for Q2 2025, down 6.91% from a year ago — trailing twelve months through Jun 2025 was $256000.0 (down 6.91% YoY), and the annual figure for FY2024 was $282000.0, down 4.41%.
  • Operating Leases for Q2 2025 was $256000.0 at Utah Medical Products, down from $282000.0 in the prior quarter.
  • Over the last five years, Operating Leases for UTMD hit a ceiling of $396000.0 in Q4 2021 and a floor of $256000.0 in Q2 2025.
  • Median Operating Leases over the past 5 years was $322000.0 (2021), compared with a mean of $322058.8.
  • Peak annual rise in Operating Leases hit 18.21% in 2021, while the deepest fall reached 18.56% in 2021.
  • Utah Medical Products' Operating Leases stood at $396000.0 in 2021, then fell by 13.89% to $341000.0 in 2022, then decreased by 13.49% to $295000.0 in 2023, then decreased by 4.41% to $282000.0 in 2024, then dropped by 9.22% to $256000.0 in 2025.
  • The last three reported values for Operating Leases were $256000.0 (Q2 2025), $282000.0 (Q4 2024), and $299000.0 (Q3 2024) per Business Quant data.